Mitoquinone (MitoQ) is a mitochondria-targeted antioxidant. The optimal doses for Mitoquinone (MitoQ) and DecylTPP treatment are selected from dose-response experiments during 4-h cold storage (CS). Mitoquinone (MitoQ) treatment significantly reduces pancreatic oedema and neutrophil infiltration. MitoQ dose-dependently increases serum amylase with an approximate doubling at the higher dose. MitoQ treatment nearly doubles lung MPO activity induced by Caerulein with a significant increase of serum IL-6 levels also evident at 10 mg/kg.
Redox Biol. 2021 Feb;39:101786.
Stat2-Drp1 mediated mitochondrial mass increase is necessary for pro-inflammatory differentiation of macrophages
Mitoquinone mesylate purchased from AbMole
|Source||Redox Biol (2020 Oct), Figure 6, Mitoquinone mesylate (Abmole Bioscience)|
|Method||Cell culture and treatment|
|Cell Lines||BMDMs and PMs|
|Concentrations||250 and 500 nM|
|Incubation Time||15 min|
|Results||Furthermore, inhibition of mitochondrial ROS production with MitoQ abrogated LPS-induced TNF-α and IL-6 expression|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO: ≥ 18 mg/mL|
Effects of the mitochondria-targeted antioxidant mitoquinone in murine acute pancreatitis.
Huang W, et al. Mediators Inflamm. 2015;2015:901780. PMID: 25878403.
The mitochondria-targeted antioxidant mitoquinone protects against cold storage injury of renal tubular cells and rat kidneys.
Mitchell T, et al. J Pharmacol Exp Ther. 2011 Mar;336(3):682-92. PMID: 21159749.
Forodesine hydrochloride is a potent and orally active transition-state analog inhibitor of purine nucleoside phosphorylase, with IC50 values ranging from 0.48 to 1.57 nM for human, mouse, rat, monkey and dog PNP.
Esaxerenone (CS-3150) is a highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
EC5026 (BPN-19186) is a first-in-class, potent and orally active soluble inhibitor of Epoxide Hydrolase (sEH). EC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.
VPC-80051 is a novel inhibitor of hnRNP A1 that targets the hnRNP A1 RBD.
|D-Ribose 5-phosphate disodium
D-Ribose 5-phosphate disodium is an intermediate of the oxidative branch of the pentose phosphate pathway (PPP) and an end product of the nonoxidative branch of the PPP.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.